Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.59 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24626081 | 1.00 | DNM1 (0.59) | DNM1ACKR3LGALS1CA1CA2 | |
| SCHEMBL24626294 | 0.92 | DNM1 (0.61) | DNM1ACKR3LGALS1CA1CA2 | |
| SCHEMBL24626478 | 0.92 | DNM1 (0.61) | DNM1ACKR3LGALS1CA1CA2 | |
| SCHEMBL24626059 | 0.89 | DNM1 (0.49) | DNM1ACKR3LGALS1NPSR1TP53 | |
| SCHEMBL24626064 | 0.89 | DNM1 (0.49) | DNM1ACKR3LGALS1NPSR1TP53 | |
| SCHEMBL14015340 | 0.89 | DNM1 (0.62) | DNM1ACKR3LGALS1CA1CA2 | |
| SCHEMBL31564882 | 0.85 | DNM1 (0.45) | DNM1ACKR3LGALS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12946150 | 0.83 | DNM1 (0.47) | DNM1ACKR3LGALS1NPSR1TP53 | |
| SCHEMBL24754677 | 0.83 | DNM1 (0.63) | DNM1ACKR3LGALS1CA1CA2 | |
| SCHEMBL24625970 | 0.82 | DNM1 (0.46) | DNM1ACKR3LGALS1ALDH1A1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220065-A1 | ADDITIVE FOR ELECTROPLATING SOLUTIONS, ELECTROPLATING SOLUTION, ELECTROPLATING METHOD AND NOVEL COMPOUND | ADEKA CORPORATION (JP) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220065-A1 | ADDITIVE FOR ELECTROPLATING SOLUTIONS, ELECTROPLATING SOLUTION, ELECTROPLATING METHOD AND NOVEL COMPOUND | SLC26A3, CLCN2, AP1M1 | DNM1 1003/4885ACKR3 1385/4885LGALS1 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.